Items where authors include "Dimopoulos, MA"

Article

Dimopoulos, MA, Moreau, P, Terpos, E et al. (14 more authors) (2022) Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. Annals of Oncology, 33 (9). p. 988. ISSN 0923-7534

Dimopoulos, MA, Moreau, P, Terpos, E et al. (15 more authors) (2022) Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Ann Oncol 2021; 32(3): 309-322]. Annals of Oncology, 33 (1). p. 117. ISSN 0923-7534

Ludwig, H, Sonneveld, P, Facon, T et al. (33 more authors) (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology, 8 (12). e934-e946. ISSN 2352-3026

Moreau, P, Kumar, SK, San Miguel, J et al. (67 more authors) (2021) Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22 (3). e105-e118. ISSN 1470-2045

Dimopoulos, MA, Moreau, P, Terpos, E et al. (14 more authors) (2021) Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 5 (2). e528. ISSN 2572-9241

Kaufman, JL, Dimopoulos, MA, White, D et al. (26 more authors) (2020) Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer Journal, 10 (11). 111. ISSN 2044-5385

Terpos, E, Engelhardt, M, Cook, G orcid.org/0000-0001-7196-7364 et al. (15 more authors) (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 34. pp. 2000-2011. ISSN 0887-6924

Bahlis, NJ, Dimopoulos, MA, White, DJ et al. (16 more authors) (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 34. pp. 1875-1884. ISSN 0887-6924

Moreau, P, Sonneveld, P, Boccadoro, M et al. (13 more authors) (2019) Chimeric Antigen Receptor T-Cell Therapy For Multiple Myeloma: A Consensus Statement From The European Myeloma Network. Haematologica, 104 (12). pp. 2358-2360. ISSN 0390-6078

Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078

Dimopoulos, MA, Gay, F, Schjesvold, F et al. (24 more authors) (2019) Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 393 (10168). pp. 253-264. ISSN 0140-6736

Dimopoulos, MA, San-Miguel, J, Belch, A et al. (30 more authors) (2018) Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX. Haematologica, 103 (12). pp. 2088-2096. ISSN 0390-6078

Ludwig, H, Delforge, M, Facon, T et al. (29 more authors) (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32 (7). pp. 1542-1560. ISSN 0887-6924

Dimopoulos, MA, Kaufman, JL, White, D et al. (8 more authors) (2018) A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clinical Lymphoma Myeloma and Leukemia, 18 (3). 163-173.e6. ISSN 2152-2650

Conference or Workshop Item

Kaufman, JL, Usmani, SZ, San-Miguel, J et al. (16 more authors) (2020) Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: 61st American Society of Hematology (ASH) Annual Meeting, 07-10 Dec 2019, Orlando, Florida, USA.

Proceedings Paper

Bahlis, N, Dimopoulos, MA, White, DJ et al. (14 more authors) (2018) Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Moreau, P, White, D, Benboubker, L et al. (12 more authors) (2018) Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux). In: Haematologica: the hematology journal. 1st European Myeloma Network Meeting, 19-21 Apr 2018, Turin, Italy. Ferrata Storti Foundation , p. 31.